Phibro Animal Health (PAHC) is a US-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of
Phibro Animal Health (PAHC) has a market capitalization of approximately
Phibro Animal Health's trailing twelve-month P/E ratio is 14.5x, with a price-to-book (P/B) of 3.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Phibro Animal Health runs a net profit margin of 6.3%, a gross margin of 32.5%, and an operating margin of 12.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Phibro Animal Health reported revenue of
Phibro Animal Health offers a trailing dividend yield of about 1.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Phibro Animal Health carries a debt-to-equity ratio of 2.18x and a current ratio of 3.17x, with a market beta of 0.46. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Phibro Animal Health (PAHC) the key facts are: market cap
Get Phibro Animal Health's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.